HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2005.042143v1 65/5/564    most recent Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Efthimiou, P Articles by Bielory, L Search for Related Content PubMed PubMed Citation Articles by Efthimiou, P Articles by Bielory, L

Diagnosis and management of adult onset Still’s disease

¹ Department of Medicine, Division of Allergy, Immunology, and Rheumatology, New Jersey Medical School, UMDNJ, Newark, NJ 07101, USA
² Department of Medicine, Weill Medical College of Cornell University, NY, NY 10021, USA

Correspondence to:
Correspondence to:
Dr P Efthimiou
90 Bergen Street, DOC#4700, Newark, NJ 07103, USA; efthimpv{at}umdnj.edu

ABSTRACT
Background: Adult onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown aetiology that is responsible for a significant proportion of cases of fever of unknown origin and can also have serious musculoskeletal sequelae.

Objective: To assess and synthesise the evidence for optimal diagnosis and management of AOSD.

Methods: The key terms, adult onset Still’s disease, AOSD, adult Still’s disease, ASD, Still’s disease were used to search Medline (1966–2005) and PubMed (1966–2005) for all available articles in the English language. Clinically relevant articles were subsequently selected. Bibliographies, textbooks, and websites of recent rheumatology conferences were also assessed.

Results: Data on diagnosis and treatment of AOSD are limited in the medical literature and consist mainly of case reports, small series, and modest scale retrospective studies. Diagnosis is clinical and requires exclusion of infectious, neoplastic, and other autoimmune diseases. Laboratory tests are non-specific and reflect heightened immunological activity. Treatment comprises non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressive drugs (methotrexate, leflunomide, gold, azathioprine, ciclosporin A, cyclophosphamide), and intravenous gammaglobulin. The recent successful application of biological agents (anti-tumour necrosis factor, anti-interleukin (IL)1, anti-IL6), often in combination with traditional immunosuppressive drugs, has been very promising.

Conclusions: AOSD often poses a diagnostic and therapeutic challenge and clinical guidelines are lacking. The emergence of validated diagnostic criteria, discovery of better serological markers, and the application of new biological agents may all provide the clinician with significant tools for the diagnosis and management of this complex systemic disorder.

Abbreviations: ANA, antinuclear antibodies; AOSD, adult onset Still’s disease; ASD, adult Still’s disease; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; IFN, interferon ; IL, interleukin; JIA, juvenile idiopathic arthritis; IVIG, intravenous gammaglobulin; LFTs, liver function tests; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor; TNF, tumour necrosis factor ; TRAPS, TNF receptor associated periodic syndrome; WBC, white blood cell

Keywords: adult onset Still’s disease; biological agents; anti-cytokine treatment

eLetters: